Recent Company News

• 04:04 PM ET May 15, 2025
  

  Trinity Biotech reports Q4 EPS ($1.28) vs year-ago $0.72 ($0.84, 0.00)

• 07:36 AM ET Mar 13, 2025
  

  Trinity Biotech appoints Barclays as financial advisor to support its ongoing strategic realignment ($0.68, 0.00)

• 08:31 AM ET Feb 28, 2025
  

  Trinity Biotech obtains additional $4M in debt financing from primary lender Perceptive Advisors ($0.75, 0.00)

• 07:40 AM ET Feb 06, 2025
  

  Trinity announces new findings from its latest pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system ($0.86, 0.00)

• 05:36 PM ET Jan 29, 2025
  

  Trinity Biotech provides update on potential impacts of US Executive Order on Foreign Aid around the company's rapid HIV testing - 6-K ($1.32, 0.00)

• 07:23 AM ET Jan 28, 2025
  

  Trinity Biotech announces results from pre-pivotal trial of disruptive continuous glucose monitoring (CGM) technology ($0.76, 0.00)

• 08:41 AM ET Dec 24, 2024
  

  Trinity Biotech amends credit agreement ($0.90, 0.00)

• 11:02 AM ET Dec 18, 2024
  

  Trinity Biotech receives early approval from WHO to begin offshore manufacturing of TrinScreen HIV & Uni-Gold HIV ($0.83, -0.02)

• 09:04 AM ET Nov 15, 2024
  

  Trinity Biotech reports Q3 EPS ($0.46) vs FactSet ($0.54) [1 est] ($1.48, 0.00)

• 08:48 AM ET Oct 25, 2024
  

  Trinity Biotech announces investment in Novus Diagnostics ($1.83, 0.00)